Lupin gets USFDA nod for generic tablets to treat excessive daytime sleepiness
Cite this
Citations are auto-generated; verify before publishing. The analysis classification is PolicyDhara's, not the source's.
Research or analytical publication — an evidence-based assessment informing policy design and evaluation. Shapes the intellectual framework within which policy debates occur.
Summary
Lupin’s USFDA approval for Pitolisant tablets expands its US generic portfolio, adding a bioequivalent treatment option for excessive daytime sleepiness in two approved strengths.